Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease

• Egile Nagusiak: Sara Salvador-Martín (Egilea), Bartosz Kaczmarczyk (Egilea), Rebeca Álvarez (Egilea), Víctor Manuel Navas-López (Egilea), Carmen Gallego-Fernández (Egilea), Ana Moreno-Álvarez (Egilea), Alfonso Solar-Boga (Egilea), Cesar Sánchez (Egilea), Mar Tolin (Egilea), Marta Velasco (Egilea), Rosana Muñoz-Codoceo (Egilea), Alejandro Rodriguez-Martinez (Egilea), Concepción A. Vayo (Egilea), Ferrán Bossacoma (Egilea), Gemma Pujol-Muncunill (Egilea), María J. Fobelo (Egilea), Antonio Millán-Jiménez (Egilea), Lorena Magallares (Egilea), Eva Martínez-Ojinaga (Egilea), Inés Loverdos (Egilea), Francisco J. Eizaguirre (Egilea), José A. Blanca-García (Egilea), Susana Clemente (Egilea), Ruth García-Romero (Egilea), Vicente Merino-Bohórquez (Egilea), Rafael González de Caldas (Egilea), Enrique Vázquez (Egilea), Ana Dopazo (Egilea), María Sanjurjo-Sáez (Egilea), Luis A. López-Fernández (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An o...